Filing summary
Issuer and period: This is Targacept, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2015, signed July 31, 2015. The filing does not identify Gyre Therapeutics, Inc. as the issuer.
Business context
Targacept was a clinical-stage biopharmaceutical company whose development programs had suffered disappointing trial results. It had no plans to continue developing its neuronal nicotinic receptor (NNR) candidates internally and was seeking to out-license or sell those assets. Its principal strategic focus was a proposed merger with Catalyst Biosciences, subject to closing conditions and shareholder approval.
Financial results and liquidity
Amounts below are in millions of dollars, except per-share data.
| Metric | Three months ended June 30, 2015 | Three months ended June 30, 2014 | Six months ended June 30, 2015 | Six months ended June 30, 2014 |
|---|---|---|---|---|
| Operating revenue | $0.000 | $0.036 | $0.060 | $0.123 |
| Research and development expense | $0.642 | $5.408 | $2.982 | $14.488 |
| General and administrative expense | $2.747 | $2.867 | $6.134 | $5.630 |
| Net loss | $(4.336) | $(8.136) | $(11.088) | $(23.135) |
| Net loss per share | $(0.13) | $(0.24) | $(0.33) | $(0.69) |
| Cash used in operating activities | Not presented by quarter | $(9.844) | $(23.759) |
- At June 30, 2015, cash and cash equivalents were $78.2 million and marketable securities were $22.4 million, for total cash and investments of $100.6 million, down from $110.8 million at December 31, 2014.
- Total assets were $101.2 million; total liabilities were $1.6 million, all current. No debt was reported on the balance sheet.
- Cash and cash equivalents increased by $21.8 million during the first half, primarily because of $31.6 million in proceeds from sales of marketable securities. This was a shift in liquid investments, not operating cash generation.
- No meaningful gross margin was reported because operating revenue was negligible. The filing does not provide a clear gross-margin figure.
Changes, outlook, and unusual items
- First-half net loss narrowed by $12.0 million year over year, mainly as R&D spending fell $11.5 million after major clinical trials ended and staffing was reduced. Lower income-tax expense versus 2014 also contributed. G&A rose $0.5 million, principally due to $1.9 million of merger-related costs.
- Management reported a workforce of 10 at June 30 after reductions during 2015. First-half reduction-in-force expense was $2.0 million, including $0.7 million of non-cash stock compensation; the filing says none remained to be paid. A separate $0.1 million impairment was recorded on furniture and equipment classified as held for sale.
- Management expected R&D expense for the remainder of 2015 to be substantially below first-half and comparable 2014 levels, following completion of the TC-6499 exploratory trial in April. This was not formal earnings guidance.
- Management expected existing capital resources to fund operations through completion of the proposed merger. If it did not close, future capital needs were difficult to forecast; management cited potential financing needs and possible dilution.
- Under the proposed transaction, Catalyst holders were expected to own approximately 58% and Targacept holders approximately 42% of the combined company immediately after closing. Before closing, Targacept expected to distribute approximately $19 million in cash and $37 million principal amount of non-interest-bearing redeemable convertible notes. Notes were convertible within 30 months at $9.19 per share, subject to the contemplated 7-for-1 reverse split. The distribution was contingent on the merger closing.
- The merger closing had been delayed from the second quarter to the third quarter of 2015 after Pfizer terminated its agreement with Catalyst; Targacept said the delay reduced the anticipated cash dividend from about $20 million to about $19 million. The filing also cited potential termination fees, including $3.22 million payable by Targacept in certain circumstances, and risks of further financing needs if notes were redeemed rather than converted.
Key investor verification points
- Confirm the issuer: this filing is for Targacept, Inc., not Gyre Therapeutics, Inc.
- Verify whether the Catalyst merger closed, the final transaction terms, the reverse split, and the amount and form of any shareholder distribution.
- Assess the notes’ redemption and conversion provisions and the effect of any cash repayment on the combined company’s liquidity and dilution.
- Track cash burn separately from proceeds of investment sales, and confirm the company’s post-merger or standalone funding runway.
- Review the status and monetization prospects of Targacept’s NNR assets, which management did not plan to develop internally, and the risks to their intellectual-property value.